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Abstract 
Purpose: Angiosarcoma of the breast is a rare, malignant tumor for which little is known 
regarding prognostic indicators and optimal therapeutic regimens. To address this issue, 
we performed a retrospective analysis of breast angiosarcoma cases seen at Stanford 
University along with immunohistochemical analysis for markers of angiogenesis.  
Methods: Breast angiosarcoma cases seen between 1980 and 2008 were examined. 
Viable tissue blocks were analyzed for expression of vascular endothelial growth factor 
and its receptors.  
Results: A total of 16 cases were identified. Data was collected regarding epidemiology, 
treatment, response rates, disease-free survival, and the use of various imaging 
modalities. Five tissue blocks remained viable for immunohistochemical analysis. 
Vascular endothelial growth factor-A was positively expressed in 3 of these samples.  
Conclusion: Angiosarcoma of the breast is an aggressive malignancy with a propensity 
for both local recurrence and distant metastases. Angiogenesis inhibition may represent 
a novel therapeutic modality in this rare, vascular malignancy. 
 
Introduction 
Sarcomas of the breast are rare, malignant tumors of mesenchymal origin. Within this 
cohort, angiosarcoma represents one of the most common histological subtypes. 
Unfortunately, these tumors tend to be aggressive with high recurrence rates and an 
overall poor prognosis. Total mastectomy remains the primary treatment for breast  
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angiosarcoma (BAs). The use of neoadjuvant and adjuvant cytotoxic chemotherapy, 
typically with anthracycline-ifosfamide and gemcitabine-taxane regimens, has been 
previously reported with variable success [1]. Given the endothelial origin of BAs, 
angiogenesis inhibition represents a potentially attractive therapeutic modality. 
The present study is a single-institution, retrospective analysis of all BAs cases seen at 
Stanford University Medical Center (SUMC). Clinical and pathologic data along with 
immunohistochemical (IHC) profiling of vascular endothelial growth factor (VEGF) and 
VEGF receptors (VEGFR) will be presented. 
Materials and Methods 
Databases within SUMC’s divisions of pathology, oncology, and radiation oncology were 
independently searched to extract all known BAs patients seen between 1980 and 2008. Various tumor 
characteristics, including location, size, grade, and stage, were examined. In those patients with a history 
of prior breast malignancy, efforts were made to determine their location, histological subtype, 
treatment, and complications, including significant lymphedema. 
Primary treatment, including radiation, surgery, and chemotherapy, was documented. Disease-free 
dates were defined as the date of primary surgical intervention in patients with negative pathologic 
margins and without known metastases. In instances of disease recurrence, salvage therapies and 
response were documented. Disease-free survival (DFS) was defined as the date of pathologic diagnosis 
to the date of pathologically confirmed disease recurrence.  
The use of various imaging modalities in establishing the diagnosis of BAs, including 
mammography, ultrasonography, and breast magnetic resonance imaging (MRI) was also evaluated. 
Finally, menopausal status at diagnosis and pertinent familial histories of breast cancer and sarcoma 
were established. 
For immunohistochemistry, slides were cut at 4 mm, deparaffinized in xylene and hydrated in a 
graded series of alcohol. The primary antibodies used were: rabbit anti-human VEGFA (A-20) 
polyclonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, Calif., USA; unit # sc-152), goat anti-
human VEGFB (N-19) polyclonal antibody (Santa Cruz Biotechnology, Inc.; unit # sc-1878), goat anti-
human VEGFC (C-20) polyclonal antibody (Santa Cruz Biotechnology, Inc.; unit # sc-1881), goat anti-
human VEGFD (N-19) polyclonal antibody (Santa Cruz Biotechnology, Inc.; unit # sc-7603), mouse 
anti-human VEGFR1 monoclonal antibody (Santa Cruz Biotechnology, Inc.; unit # sc-65442), rabbit 
anti-human VEGFR2 polyclonal antibody (Abcam, Cambridge, UK; unit # ab45010), and mouse anti-
human VEGFR3 monoclonal antibody (Abcam; unit # ab51496). The antigen retrieval solution was 
EDTA, pH 8. Slides were boiled by microwaving in antigen retrieval solution for 12 min. IHC reactions 
were visualized using rabbit, goat, or mouse versions of the biotin-free EnVision + system (DAKO, 
Carpinteria, Calif., USA) using diaminobenzidine. 
Results 
A total of 16 female patients with pathologic diagnoses of BAs were identified. 
Epidemiologic and pathologic data are presented in table 1. Prior breast malignancies 
were present in 8 patients, of which 6 were infiltrating ductal carcinomas and 2 were 
infiltrating lobular carcinomas. Only 1 patient had a prior history of longstanding 
lymphedema. Previous ipsilateral breast irradiation was seen in 6 cases, and these patients 
tended to present at an older age (median 74 years, range 63–80 years). The average 
latency from irradiation to diagnosis of angiosarcoma in this cohort was 78 months 
(range 56–134 months). 
Primary and salvage surgery, chemotherapy, and radiotherapy are presented in table 2. 
Disease recurrence was documented in 5 of 16 patients at a median interval of 7 months 
(range 1–22 months). The Kaplan-Meier curve for DFS is depicted in fig. 1.   
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Five tissue blocks of adequate viability were available for IHC analysis. Several 
antibodies were tested, including those against VEGF-A, VEGF-B, VEGF-C, VEGF-D, 
VEGFR-1, VEGFR-2, and VEGFR-3. Of these, clear positive and negative staining on 
archival tissue was demonstrated only for VEGF-A, VEGF-B, and VEGFR-2. Positive 
VEGF-A staining was noted in 3 of the 5 samples. VEGF-B and VEGFR-2 staining was 
negative in all 5 samples. Representative IHC sections are shown in fig. 2.  
Discussion 
Sarcomas of the breast are rare, malignant tumors that occur at an annual frequency of 
4.5 cases per 1 million women [2]. Within this group, angiosarcoma occurs with an 
annual incidence between 0.002 and 0.005% [3]. A recent review of BAs cases published 
to date established a median age at presentation of 70 (63 in the present study) and a 
median latency from prior radiotherapy to diagnosis of BAs as 72 months (78 months in 
the present study) [4]. 
In our series, the predominant imaging modalities prior to diagnosis were 
mammography and ultrasonography, whereas MRI was performed in only 1 patient. The 
optimal type of imaging for diagnosis of BAs is not known. Mammography may fail to 
identify 33% of BAs in contrast to only 9% of breast carcinomas [5, 6]. Using ultrasound, 
BAs may appear hyperechogenic and well circumscribed with posterior shadowing and, 
uncommonly, coarse calcification. Using MRI, BAs may have striking T2 signal, 
peripheral vascular channels, and either non-enhancement or enhancement without 
washout due to the presence of blood-filled vascular spaces. Fig. 3 highlights 
representative radiologic findings in a 31-year-old female with primary BAs. 
An interesting departure of our data from that previously published is a relatively 
lower burden of recurrent disease. Here, we report a recurrence rate of 37.5% over a 
median follow-up interval of 8 months. Previous estimates have reported variable 
recurrence rates ranging from 25–73% [3, 7]. This may partially be explained by our 
shorter follow-up interval. However, our population also contained a relatively greater 
percentage of patients treated with modified radical mastectomy (25%) over simple 
mastectomy (75%). Since the optimal extent of primary surgical resection has never been 
prospectively examined, it is difficult to gauge the magnitude of this effect. Previous 
retrospective analyses have reported 5 year DFS and overall survival of 44 and 61%, 
respectively [1]. Collectively, our data confirm BAs as an aggressive vascular malignancy 
of elderly women with a propensity for both local recurrence and distant metastases. 
VEGF and VEGFR represent critical components in the process of angiogenesis, 
vascular permeability, and metastasis [8]. The VEGF structural family includes VEGF-A, 
VEGF-B, VEGF-C, and VEGF-D. Of these, VEGF-A is the major proangiogenic agent 
through its interactions with VEGFR-2, also known as kinase-insert domain-containing 
receptor (kdr). Although VEGF-A binds VEGFR-1, also known as fms-like tyrosine 
kinase (flt), the role of this interaction remains unclear. 
Our series did not suggest widespread VEGF-A, VEGF-B, or VEGFR-2 expression in 
BAs. One of the 3 patients with positive VEGF-A staining in our series was a previously 
healthy 31-year-old female with primary BAs. It remains unclear whether primary BAs is 
a distinct clinical entity in comparison to secondary BAs in the previously irradiated 
breast. A prior report comparing 32 primary BAs cases with 23 secondary cases in 
previously irradiated patients found the former group to have better DFS and overall 
survival within the first 3 years, but no difference in overall survival curves [9].  
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The possibility of targeted anti-angiogenic therapy in the treatment of BAs remains 
intriguing. Recent IHC data from Itakura et al. [10] demonstrated positive VEGF-A 
expression in 32 of 34 (94%) angiosarcomas, although none of these were breast 
malignancies. A previous study demonstrated positive VEGF staining in 5 of 6 (83%) BAs, 
although correlating clinicopathologic and epidemiologic data were not presented [11]. 
The absence of widespread VEGF positivity in the current study does not preclude the 
use of anti-angiogenic agents in BAs treatment. For example, data from other tumor 
models has suggested that VEGF levels may not be predictive of clinical response to 
bevacizumab (Genentech, South San Francisco, Calif., USA), a monoclonal antibody 
against VEGF approved for treatment in metastatic breast, lung, and colon cancer [12]. 
Furthermore, therapy with paclitaxel, an alkaloid ester derived from the yew tree, has 
demonstrated efficacy in angiosarcoma. A phase II clinical trial of weekly paclitaxel for 
patients with metastatic or unresectable angiosarcoma has been completed [13]. In this 
analysis, a 19% overall response rate and 24% non-progression rate were observed at 6 
months. Additionally, 3 patients who were unresectable at diagnosis achieved a partial 
response, permitting curative intent surgery. Two of these patients attained a complete 
remission, highlighting the mainstay of surgical therapy as primary treatment. Paclitaxel’s 
cytotoxic effects have traditionally been ascribed to enhanced tubulin polymerization 
resulting in mitotic arrest [14]. However, paclitaxel has also been noted to have intrinsic 
anti-angiogenic activity that, at low concentrations, occurs without effecting microtubule 
function [15]. Hence, angiogenesis inhibition via anti-VEGF therapy may indeed 
represent a viable treatment. An open-label phase II study of single agent bevacizumab in 
angiosarcoma is currently ongoing. 
Although this vascular malignancy remains rare, the increasing use of breast-
conserving therapy with adjuvant radiotherapy may contribute to a rising incidence in the 
coming decades. Larger descriptive series, particularly documenting outcomes with 
neoadjuvant and adjuvant chemo- and radiotherapy, are needed. The ultimate efficacy of 
targeted anti-VEGF treatment will depend upon data from ongoing clinical trials. 
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Table 1. Epidemiologic and pathologic data 
Age at diagnosis, years   
Range  .23–80 
Median  .63 
Gender  
Female  .16 (100%) 
Tumor size, cm   
Range 1.5–16.6 
Median 5.5 
Tumor grade   
High  .06 (37.5%) 
Intermediate  0.3 (18.75%) 
Low  .04 (25%) 
Unavailable  0.3 (18.75%) 
Overall stage   
I  .02 (12.5%) 
II  0.8 (50%) 
III  .00 (0%) 
IV  0.1 (6.25%) 
Incomplete  .05 (31.25%) 
Breast location   
Right  0.7 (43.75%) 
Left  .09 (56.25%) 
History of prior ipsilateral breast malignancy   
IDC  0.6 (37.5%) 
ILC  .02 (12.5%) 
History of prior ipsilateral breast irradiation  0.6 (37.5%) 
History of significant lymphedema  .01 (6.25%) 
History of malignancy in 1st degree relative   
Sarcoma  0.0 (0%) 
Breast  .02 (12.5%) 
Menopausal status at diagnosis   
Pre  0.6 (37.5%) 
Post  .09 (56.25%) 
Unavailable  0.1 (6.25%) 
Imaging modalities prior to diagnosis   
Ultrasound  .02 (12.5%) 
Mammography  0.9 (56.25%) 
Ultrasound and mammography  .03 (18.75%) 
Breast MRI  0.1 (6.25%) 
IDC = Infiltrating ductal carcinoma; ILC = infiltrating lobular carcinoma. 
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Table 2. Primary and salvage therapies 
Primary surgical therapy   
SM 12  (75%) 
MRM  04 (25%) 
Primary adjuvant chemotherapy   
DC  01 (6.25%) 
DI  01 (6.25%) 
EI  01 (6.25%) 
Primary radiotherapy  03 (18.75%) 
Recurrence of disease   
Total  06 (37.5%) 
Chest wall  04 (25%) 
Liver  02 (12.5%) 
Lungs  02 (12.5%) 
Brain  01 (6.25%) 
Tonsil  01 (6.25%) 
Salvage surgery   
Total  04  
Local excision  02 (12.5%) 
Radical chest dissection  01 (6.25%) 
Stereotactic intracranial resection  01 (6.25%) 
Salvage radiotherapy  01 (6.25%) 
Salvage chemotherapy  02 (12.5%) 
Response to salvage therapy   
Progression  04 (25%) 
Disease-free  01 (6.25%) 
SM = Simple mastectomy; MRM = modified radical mastectomy; DC = doxorubicin/cyclophos-
phamide; DI = doxorubicin/ifosfamide; EI = epirubicin/ifosfamide. 
 
 
 
 
Fig. 1. Kaplan-Meier curve depicting disease-free survival. 
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Fig. 2. VEGF immunostaining in representative full cross-sections of angiosarcoma cases. a High-level 
immunostaining for VEGF-A; b low-level immunostaining for VEGF-A; c absence of staining for 
VEGF-B; d absence of staining for VEGFR-2. All images at 400×. 
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Fig. 3. Primary angiosarcoma of the left breast in a 31-year-old female. Initial mammography and 
ductogram were negative. However, spot images from the post-ductogram mammographic study (a) 
revealed a subtle mixed density lesion with both lucent and dense foci and lobulated, well-circumscribed 
margins (arrow) that were not appreciated on the initial mammogram. Ultrasound (b, c) of this location 
revealed a well-circumscribed heterogeneously echogenic lesion with posterior shadowing but no 
detectable flow. MRI (d) demonstrated a 1.3-cm lesion with high T2 signal but no significant 
enhancement (arrow). Mammogram of the post-excision specimen (e) demonstrates the sharply 
marginated mass with coarse heterogeneous stroma (arrow). Pathology indicated that this 
angiosarcoma was low-grade, which may account for the lack of vascularity and enhancement on 
ultrasound and MRI. 
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